• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

    1.920 +0.020 (+1.05%)
    Streaming Delayed Price Updated: 2:00 PM EDT, Mar 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 444,003
    Open 1.900
    Bid (Size) 1.910 (300)
    Ask (Size) 1.930 (500)
    Prev. Close 1.900
    Today's Range 1.870 - 1.990
    52wk Range 1.410 - 4.340
    Shares Outstanding 27,132,588
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Gain Therapeutics to Present at the 38th Annual ROTH Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Which stocks are moving on Wednesday? ↗
    Via Chartmill

    Performance

    YTD
    -39.6%
    -39.6%
    1 Month
    +6.1%
    +6.1%
    3 Month
    -14.7%
    -14.7%
    6 Month
    +12.9%
    +12.9%
    1 Year
    -22.3%
    -22.3%

    More News

    Read More
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Keep an eye on the top gainers and losers in Thursday's session. ↗
    Via Chartmill
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics to Present at Neuroscience 2025
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics to Attend the 2025 Maxim Growth Summit
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
    From Gain Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Gain Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Gain Therapeutics, Inc. - Common Stock trade on?
    Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?
    The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market
    What is the current price of Gain Therapeutics, Inc. - Common Stock?
    The current price of Gain Therapeutics, Inc. - Common Stock is 1.920
    When was Gain Therapeutics, Inc. - Common Stock last traded?
    The last trade of Gain Therapeutics, Inc. - Common Stock was at 03/20/26 02:00 PM ET
    What is the market capitalization of Gain Therapeutics, Inc. - Common Stock?
    The market capitalization of Gain Therapeutics, Inc. - Common Stock is 52.09M
    How many shares of Gain Therapeutics, Inc. - Common Stock are outstanding?
    Gain Therapeutics, Inc. - Common Stock has 52M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.